Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 14; pp. 15176 - 15186
• Main Authors: Liang, Yi‐Hsin, Chen, Kuo‐Hsing, Shao, Yu‐Yun
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.07.2023; John Wiley and Sons Inc; Wiley
• Subjects: Bevacizumab; Cancer therapies; cetuximab; Chemotherapy; Clinical outcomes; Clinical trials; Colorectal cancer; Colorectal carcinoma; Demographics; Drug dosages; EGFR; Epidermal growth factor; Epidermal growth factor receptors; Histology; K-Ras protein; Lung cancer; Metastases; Metastasis; metastatic colorectal cancer; Monoclonal antibodies; Multivariate analysis; National health insurance; panitumumab; Patients; Population; secondary surgery; Surgery; Tumors; Variables; Taiwan; bevacizumab; cetuximab; metastatic colorectal cancer; panitumumab; secondary surgery; EGFR

Background The first‐line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti‐epidermal growth factor receptor (anti‐EGFR) monoclonal antibody (mAb) is the more effective addition to a chemoth...